Liberum Capital restated their hold rating on shares of Shire PLC (LON:SHP) in a research report report published on Wednesday, June 28th. Liberum Capital currently has a GBX 4,900 ($63.84) price target on the biopharmaceutical company’s stock.
Several other brokerages also recently weighed in on SHP. J P Morgan Chase & Co restated an overweight rating and set a GBX 6,000 ($78.17) price objective on shares of Shire PLC in a research report on Monday, March 27th. Citigroup Inc. restated a buy rating on shares of Shire PLC in a research report on Wednesday, April 12th. Barclays PLC reiterated an overweight rating and issued a GBX 6,500 ($84.68) price target on shares of Shire PLC in a research report on Wednesday, May 3rd. Credit Suisse Group reiterated an outperform rating and issued a GBX 5,400 ($70.35) price target on shares of Shire PLC in a research report on Wednesday, May 3rd. Finally, Deutsche Bank AG reiterated a buy rating and issued a GBX 6,100 ($79.47) price target on shares of Shire PLC in a research report on Friday, May 19th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. Shire PLC has a consensus rating of Buy and an average target price of GBX 6,024 ($78.48).
Shire PLC (LON:SHP) traded down 2.03% during mid-day trading on Wednesday, hitting GBX 4262.50. The company had a trading volume of 1,976,387 shares. The stock’s market capitalization is GBX 38.54 billion. Shire PLC has a 1-year low of GBX 4,025.00 and a 1-year high of GBX 5,377.00. The stock has a 50 day moving average price of GBX 4,289.98 and a 200-day moving average price of GBX 4,559.16.
TRADEMARK VIOLATION NOTICE: This piece was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/07/29/shire-plc-shp-stock-rating-reaffirmed-by-liberum-capital-updated-updated-updated.html.
In related news, insider Dominic Blakemore purchased 152 shares of the firm’s stock in a transaction dated Friday, June 30th. The stock was acquired at an average price of GBX 4,255 ($55.43) per share, with a total value of £6,467.60 ($8,425.74).
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.